280 related articles for article (PubMed ID: 17296814)
1. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
Markman M
Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for ovarian cancer.
Kelland LR
Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
[TBL] [Abstract][Full Text] [Related]
3. Topotecan: weighing in when there are many options.
Penson RT; Seiden MV
Oncologist; 2005 Oct; 10(9):698-700. PubMed ID: 16249349
[TBL] [Abstract][Full Text] [Related]
4. Innovative therapies for advanced ovarian cancer.
Trimble EL
Semin Oncol; 2000 Jun; 27(3 Suppl 7):24-30. PubMed ID: 10952123
[TBL] [Abstract][Full Text] [Related]
5. Use of CA-125 to assess response to new agents in ovarian cancer trials.
Rustin GJ
J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
[TBL] [Abstract][Full Text] [Related]
6. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
7. Promising new developments in the systemic treatment of ovarian cancer.
Reed E
J Assoc Acad Minor Phys; 1994; 5(1):16-21. PubMed ID: 7513218
[TBL] [Abstract][Full Text] [Related]
8. Investigational agents for epithelial ovarian cancer.
Muggia F; Kosloff R
Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
[TBL] [Abstract][Full Text] [Related]
9. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
10. Pros and cons for systemic therapy in recurrent ovarian cancer.
Oskay-Ozcelik G; Sehouli J
Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
13. New drugs for the treatment of cancer, 1990-2001.
Geffen DB; Man S
Isr Med Assoc J; 2002 Dec; 4(12):1124-31. PubMed ID: 12516906
[TBL] [Abstract][Full Text] [Related]
14. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
15. Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity.
Markman M
Oncologist; 2005 Oct; 10(9):695-7. PubMed ID: 16249348
[TBL] [Abstract][Full Text] [Related]
16. [Intraperitoneal chemotherapy for ovarian cancer].
Noma J; Yoshida N
Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
Markman M
Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
[TBL] [Abstract][Full Text] [Related]
18. Japan works to shorten "drug lag," boost trials of new drugs.
Sinha G
J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
[No Abstract] [Full Text] [Related]
19. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
20. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]